DE60231821D1 - Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung - Google Patents

Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung

Info

Publication number
DE60231821D1
DE60231821D1 DE60231821T DE60231821T DE60231821D1 DE 60231821 D1 DE60231821 D1 DE 60231821D1 DE 60231821 T DE60231821 T DE 60231821T DE 60231821 T DE60231821 T DE 60231821T DE 60231821 D1 DE60231821 D1 DE 60231821D1
Authority
DE
Germany
Prior art keywords
recombinant
vaccines
tollwood
preparation
rabies virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60231821T
Other languages
English (en)
Inventor
Bernhard Dietzschold
Douglas Craig Hooper
Matthias J Schnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Application granted granted Critical
Publication of DE60231821D1 publication Critical patent/DE60231821D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60231821T 2001-10-10 2002-10-10 Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung Expired - Lifetime DE60231821D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32835001P 2001-10-10 2001-10-10
PCT/US2002/032475 WO2003030933A1 (en) 2001-10-10 2002-10-10 Recombinant rabies vaccine and methods of preparation and use

Publications (1)

Publication Number Publication Date
DE60231821D1 true DE60231821D1 (de) 2009-05-14

Family

ID=23280622

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60231821T Expired - Lifetime DE60231821D1 (de) 2001-10-10 2002-10-10 Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung

Country Status (6)

Country Link
US (1) US7223584B2 (de)
EP (1) EP1439856B1 (de)
AT (1) ATE427119T1 (de)
CA (1) CA2463090C (de)
DE (1) DE60231821D1 (de)
WO (1) WO2003030933A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003234090A1 (en) * 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
DE602005021636D1 (de) 2004-07-12 2010-07-15 Univ Jefferson Zusammensetzungen mit rekombinantem tollwutvirus
US7863041B2 (en) * 2005-10-14 2011-01-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus vector systems and compositions and methods thereof
US8524247B2 (en) * 2008-09-17 2013-09-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus-based recombinant immunocontraceptive compositions and methods of use
US8282939B2 (en) * 2009-09-11 2012-10-09 Thomas Jefferson University Attenuated live triple G protein recombinant rabies virus vaccine for pre- and post-exposure prophylaxis of rabies
CN101768575B (zh) * 2010-01-15 2013-06-12 中国农业科学院哈尔滨兽医研究所 双表达g基因的重组狂犬病病毒的构建及其生物学特性分析
US9248179B2 (en) 2010-06-24 2016-02-02 The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention Pan-lyssavirus vaccines against rabies
CN103323588A (zh) * 2012-03-19 2013-09-25 郑州中道生物技术有限公司 一种犬狂犬病毒抗体的检测方法及检测试剂盒
WO2014055289A1 (en) * 2012-10-01 2014-04-10 Thomas Jefferson University Immunization with rabies virus vector expressing foreign protein antigen
CN104599668B (zh) * 2014-12-18 2018-02-02 清华大学 基于稀疏矩阵快速语音识别方法和装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2693655B1 (fr) * 1992-07-20 1994-10-14 Virbac Vaccin antirabique avirulent.
US6295531B1 (en) * 1998-11-09 2001-09-25 Unisys Corporation Cool ICE data wizard
US7074413B2 (en) 2000-03-23 2006-07-11 Thomas Jefferson University Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife
US6708173B1 (en) * 2000-10-18 2004-03-16 Unisys Corporation Method and apparatus for multiple application trace streams
US6836886B2 (en) * 2001-03-19 2004-12-28 Autodesk, Inc. Method and apparatus for delivering electronic information

Also Published As

Publication number Publication date
CA2463090C (en) 2012-06-12
WO2003030933A1 (en) 2003-04-17
CA2463090A1 (en) 2003-04-17
EP1439856A1 (de) 2004-07-28
EP1439856A4 (de) 2005-01-19
EP1439856B1 (de) 2009-04-01
ATE427119T1 (de) 2009-04-15
US20030113346A1 (en) 2003-06-19
US7223584B2 (en) 2007-05-29

Similar Documents

Publication Publication Date Title
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
IL202249A (en) Nucleic Acids Encoders Human Immunodeficiency Strange Type 1 (HIV – 1) Group M Consensus Envelope Glycoproteins
HUP0303036A3 (en) Dna transfection system for the generation of infectious influenza virus
NO20001768L (no) Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
WO2005062820A3 (en) Multi plasmid system for the production of influenza virus
EP1504112A4 (de) Entwicklung einer vakzine zur prävention von infektionen mit dem filovirus bei primaten
ATE526411T1 (de) Avirulente, immunogene flavivirus-chimäre
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
NO20041157L (no) HIV-GAG kodonoptimaliserte DNA-vaksiner
DE60139026D1 (de) Lebender influenza impfstoff und verfahren zu seiner herstellung
EP1578766A4 (de) Polyvalente, primärehiv-1-glycoprotein-dna-impfstoffe und impfverfahren
AU2003246373A8 (en) Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions
FR2827605B1 (fr) Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
DE60231821D1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
DE69936337D1 (de) Verfahren zur entwicklung von einem hiv impfstoff
DK1356822T3 (da) Farmaceutiske sammensætninger, der forøger immunogeniteten af svagt immunogene antigener
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
ATE372129T1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
CY1107784T1 (el) Πρωτεϊνη συντηξης g του ihnv για διεγερση του ανοσοποιητικου συστηματος
DK1372712T3 (da) Vaccine mod equint herpesvirus
HK1048136A1 (en) Herpes viruses for immune modulation.
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
GB0006716D0 (en) Virus or viral antigen purification method and vaccine producing method

Legal Events

Date Code Title Description
8364 No opposition during term of opposition